Two new names to add to the list of Roche acquisitions.

It’s been a busy 7 days for Roche. Last Thursday they agreed an acquisition of $190 million for clinical microbiology diagnostics solutions company, GeneWEAVE BioSciences. The deal could also net GeneWEAVE an additional $235 million if product related milestones are met. As the company is integrated into Roche Molecular Diagnostics, they currently have their first system in development. vivoDX is a fully automated, random-access system designed to meet the needs of laboratories addressing multidrug-resistant organism detection and antibiotic therapy guidance. It is currently under evaluation across multiple sites in the US.

“With GeneWEAVE, we further strengthen our microbiology diagnostics offerings with cutting-edge technology that will aid in the fight against drug-resistant bacteria. This technology has the potential to provide healthcare professionals access to quick and accurate diagnoses that can lead to rapid, informed treatment decisions,” said Roland Diggelmann, COO of Roche Diagnostics. “We welcome GeneWEAVE’s employees, who will continue to focus on the development and manufacturing of diagnostics solutions based on the Smarticles™ technology.”

“We are very excited to continue developing innovative microbiologic diagnostics solutions as part of the Roche Molecular Diagnostics team,” said Steve Tablak, Chief Executive Officer of GeneWEAVE. “Roche is the ideal company to deliver on the promise of our Smarticles technology. We are fully committed to the continued success of GeneWEAVE’s employees, products and pipeline.”

A week on, and Roche have followed the news with another acquisition. This week, they have bolstered their next-generation sequencing (NGS) offering by reaching an agreement for Kapa Biosystems for an undisclosed amount. Kapa have been manufacturing custom RNA-seq preparation kit’s for Roche’s NimbleGen unit since 2013. The acquisition suggests that they enjoyed the relationship enough to take it to the next level.

“This acquisition builds on Roche’s commitment to develop a differentiated NGS portfolio that will provide our customers with a complete genetic testing solution,” said Roland Diggelmann, COO Roche Diagnostics Division. “Kapa’s technology and products complement our current expertise and offerings such as the portfolio of target enrichment products for NGS. We welcome Kapa’s employees and are looking forward to strengthening our NGS offerings with this unique technology.”

“Joining Roche provides us access to their broad product portfolio, global reach and clinical expertise that will accelerate our strategy of offering comprehensive NGS workflow solutions to more laboratories around the world,” said Paul McEwan, Co-Founder and Chief Scientific Officer of Kapa Biosystems. “We are also excited to have the opportunity to further leverage our enzyme engineering capabilities to advance the fields of genomics and sequencing, with the ultimate goal of having a more significant impact on medicine and human health.”

Roche’s recent acquisitions including Genia Technologies, Bina Technologies, Signature Diagnostics, and a majority stake in Foundation Medicine. After the collapsed deal for Illumina a couple of year’s ago, the Swiss giants have have been investing heavily to bite into the Californian’s NGS market share. As has been customary to ask – who’s next for Roche?